



15 February 2007

The Manager
Company Announcements
Australian Stock Exchange
4th Floor, 20 Bridge Street
Sydney NSW 2000

Dear Sir/Madam,

Re: RHT: Update on FibroScreen™ and FerriScan®

Resonance Health Limited is developing an innovative non-invasive diagnostic test for liver fibrosis, FibroScreen™. Due to recent shifts in the competitive landscape within which FibroScreen™ intends to operate the Company has engaged an external consultant to analyse the potential market for the service.

It should be noted that one of the potential recommendations that could be made to the Board by the consultant may be to cease further development of the FibroScreen™ technology.

Upon receipt of the consultant's recommendation, the Company will make a further announcement to the market regarding the ongoing development of the technology.

With respect to revenues derived from the Company's non-invasive tool for the measurement of liver iron concentration, FerriScan®, the previously announced arrangement with our largest customer for minimum monthly revenues of US\$100,000 has been extended through March 31 pending further negotiations. The Company expects to continue to receive revenues at some level from that customer even if the contract is renegotiated, and will provide further notice when there is additional clarity about material changes in the contract.

By Order of the Board



Paul Jobbins
Company Secretary